Back
Outlook Therapeutics Stock Price Chart
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Sell
38
OTLK
Outlook Therapeutics
Last Price:
6.06
Seasonality Move:
-9.79%
7 Day Trial
ALL ACCESS PASS
$
7
Yours Free! Top SIX AI Dividend Stocks Right Now
NO CREDIT CARD REQUIRED!- Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and OTLK is experiencing slight selling pressure.
Outlook Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 5.74 | Buy |
| 20-day SMA: | 5.42 | Buy |
| 50-day SMA: | 6.06 | Sell |
| 200-day SMA: | 7.53 | Sell |
| 8-day EMA: | 5.78 | Buy |
| 20-day EMA: | 5.64 | Buy |
| 50-day EMA: | 6 | Buy |
| 200-day EMA: | 8.13 | Sell |
Outlook Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.01 | Buy |
| Relative Strength Index (14 RSI): | 60.41 | Buy |
| Chaikin Money Flow: | -67113 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (5.08 - 5.7) | Buy |
| Bollinger Bands (100): | (5.76 - 7.98) | Sell |
Outlook Therapeutics Technical Analysis
| Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | Nov 4 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | Nov | |||||||||
| 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | 04 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Outlook Therapeutics Stock
Is Outlook Therapeutics Stock a Buy?
- Outlook Therapeutics share price is 6.04 while OTLK 8-day simple moving average is 5.74, which is a Buy signal.
- The stock price of OTLK is 6.04 while Outlook Therapeutics 20-day SMA is 5.42, which makes it a Buy.
- Outlook Therapeutics 50-day simple moving average is 6.06 while OTLK share price is 6.04, making it a Sell technically.
- OTLK stock price is 6.04 and Outlook Therapeutics 200-day simple moving average is 7.53, creating a Sell signal.
OTLK Technical Analysis vs Fundamental Analysis
Sell
38
Outlook Therapeutics (OTLK)
is a Sell
Is Outlook Therapeutics a Buy or a Sell?
-
Outlook Therapeutics stock is rated a Sell
The current Outlook Therapeutics [OTLK] share price is $6.04. The Score for OTLK is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.
Outlook Therapeutics Stock Info
Market Cap:
142.88M
Price in USD:
6.04
Share Volume:
174.21K
Outlook Therapeutics 52-Week Range
52-Week High:
12.85
52-Week Low:
4.61
Sell
38
Outlook Therapeutics (OTLK)
is a Sell
Outlook Therapeutics Share Price Forecast
-
What is the Outlook Therapeutics stock price today?
The Outlook Therapeutics stock price is 6.04 USD today. -
Will OTLK stock go up or go down?
Outlook Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Outlook Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Outlook Therapeutics is overvalued.
Is Outlook Therapeutics Stock a Buy?
- Outlook Therapeutics share price is 6.04 while OTLK 8-day exponential moving average is 5.78, which is a Buy signal.
- The stock price of OTLK is 6.04 while Outlook Therapeutics 20-day EMA is 5.64, which makes it a Buy.
- Outlook Therapeutics 50-day exponential moving average is 6.00 while OTLK share price is 6.04, making it a Buy technically.
- OTLK stock price is 6.04 and Outlook Therapeutics 200-day simple moving average is 8.13, creating a Sell signal.
Fundamental Analysis of Outlook Therapeutics
Is Outlook Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.39 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.74 per share, and an increase next year of $1.39 per share.
Technical Analysis of Outlook Therapeutics
Should I short Outlook Therapeutics stock?
- OTLK Moving Average Covergence Divergence (MACD) indicator is 0.01, suggesting Outlook Therapeutics is a Buy
- Outlook Therapeutics Relative Strength Index (RSI) is 60.41, which suggest Outlook Therapeutics is overbought
- The Bollinger Bands (25) for Outlook Therapeutics is (5.08 - 5.7), which suggest Outlook Therapeutics is a Sell
- The Bollinger Bands (100) for Outlook Therapeutics is (5.76 - 7.98), which suggest Outlook Therapeutics is a Sell
* Outlook Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.